135 results on '"Kohlschmidt J"'
Search Results
2. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia
3. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
4. Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2
5. No evidence for microsatellite instability in acute myeloid leukemia
6. Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)
7. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
8. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
9. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8
10. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
11. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia
12. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia
13. Immunomodulatory effects of benzo[a]pyren in activated bone marrow-derived macrophages: OP-065
14. PF232 PROGNOSTIC IMPACT OF THE 2017 EUROPEAN LEUKEMIANET (ELN) CLASSIFICATION OF YOUNGER ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED ON CANCER AND LEUKEMIA GROUP B (CALGB)/ALLIANCE PROTOCOLS
15. Border Shifts: On the Relationship Between Residential Care, Flight and the Police in Germany
16. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia
17. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)
18. Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)
19. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
20. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
21. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novoacute myeloid leukemia
22. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
23. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification
24. In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline
25. Mutations in the CCND1and CCND2genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia
26. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
27. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
28. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
29. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
30. Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
31. Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials.
32. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
33. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
34. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
35. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
36. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.
37. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.
38. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.
39. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes.
40. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
41. Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement.
42. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
43. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).
44. Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations.
45. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.
46. Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.
47. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.
48. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
49. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A .
50. Author Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.